Want to see ALNY full AI Analyst Report?
ALNY Stock Chart & Stats
$240.08
$10.57(3.89%)
At close: 4:00 PM EDT
$240.08
$10.57(3.89%)
Day’s Range― - ―
52-Week Range$197.81 - $495.55
Previous CloseN/A
Volume740.62K
Average Volume (3M)1.29M
Market Cap
$31.02B
Enterprise Value$41.31B
Total Cash (Recent Filing)$3.31B
Total Debt (Recent Filing)$1.27B
Price to Earnings (P/E)38.0
Beta0.94
Next Earnings
Oct 29, 2026EPS Estimate
1.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.10
Shares Outstanding133,809,110
10 Day Avg. Volume1,223,392
30 Day Avg. Volume1,288,342
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)66.01
Price to Sales (P/S)14.03
P/FCF Ratio111.94
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue8.60
Enterprise Value/Gross Profit10.79
Enterprise Value/Ebitda35.90
Forecast
1Y Price Target
$364.76Price Target Upside51.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering23
EPS Forecast (FY)6.65
Revenue Forecast (FY)$5.47B
Bulls Say, Bears Say
Bulls Say
Rapid Product AdoptionAMVUTTRA’s rapid uptake demonstrates strong commercial execution and expanding demand for Alnylam’s RNAi medicines. Reaching more than $1 billion in quarterly revenue so soon after launch can provide a durable growth platform, support operating leverage, and reinforce the company’s position in TTR treatment.
Strong Cash Generation And ProfitabilityThe recent shift to substantial profitability and cash generation strengthens Alnylam’s ability to fund clinical development, commercialization, and business expansion internally. High free-cash-flow conversion also supports earnings quality and gives management greater flexibility to sustain investment through the next several quarters.
Pipeline And Geographic ExpansionMultiple clinical programs and expansion into China and Macau broaden Alnylam’s future opportunity beyond current products and markets. Continued pipeline activity creates additional potential revenue streams, while regional partnerships can extend commercial reach without requiring the company to build every market capability alone.
Bears Say
Lowered TTR Revenue GuidanceThe guidance reduction indicates that initial demand dynamics were stronger than the sustainable near-term run rate, creating an execution risk for the TTR franchise. Although management still expects about 75% annual growth, the reset raises the importance of maintaining new-patient starts and converting broader adoption into durable revenue.
Margin Pressure And Rising InvestmentHigher royalties are reducing product-level margin just as Alnylam is increasing spending on Phase III studies and launch activities. This combination may limit operating leverage in the near term and requires continued revenue growth to offset cost expansion, particularly while several pipeline programs remain dependent on future clinical progress.
Meaningful Leverage After Prior LossesThe balance sheet is more stable than in prior loss years, but meaningful debt and the history of negative equity leave less room for earnings volatility than a consistently profitable capital structure would. If growth or margins weaken, leverage could constrain financial flexibility and compete with pipeline investment for available resources.
Alnylam Pharma News
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $197.81 and its highest was $495.55 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $31.02B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Jul 30, 2026. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.63 by -$0.42.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is 1.74.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 133,809,110 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of $1.21 in its last earnings report, missing expectations of $1.63. Following the earnings report the stock price went down -28.309%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alnylam Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$364.76 (51.93% Upside)
$364.76 (51.93% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 69%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 25.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Bullish
Bullish news 60%
Bearish news 40%
Bearish news 40%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.80%
12-Months-Change
Fundamentals
Return on Equity
93.61%
Trailing 12-Months
Asset Growth
21.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
ALNY Company Deck
ALNY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum — highlighted by record quarterly AMVUTTRA and broad TTR revenue growth, expanding prescriber base, robust cash and operating income, strategic geographic and AI partnerships, and an active pipeline with upcoming data readouts. Negative elements included a $200M downward revision to 2026 TTR guidance tied to normalization of early switch demand, a Q2 decline in collaboration revenue, margin pressure from higher royalties, increased R&D/SG&A investment, and industry uncertainty following a competitor trial failure (CARDIO-TTRansform). Management framed the guidance reduction as a learning from early launch dynamics and emphasized confidence in long-term TTR leadership and nucresiran’s prospects, indicating highlights outweigh challenges.View all ALNY earnings summariesALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
ALNY Stock 12 Month Forecast
Average Price Target
$364.76
▲(51.93% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Ionis Pharmaceuticals
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Ownership Overview
0.24% Insiders
45.01% Mutual Funds
0.34% Other Institutional Investors
30.94% Public Companies and Individual Investors